Objective This work aimed at building a population pharmacokinetic (PK) model for lamivudine (LMV), stavudine (STV) and zidovudine (ZDV), estimating their inter and intraindividual PK variability and investigating the influence of different covariates. Methods Population PK of LMV, STV and ZDV was separately evaluated from plasma concentrations obtained in 54, 39 and 27 HIV1-infected patients, respectively, enrolled in the COPHAR1-ANRS102 trial. The primary objective of this trial was to study the pharmacokinetics of indinavir (IDV) and nelfinavir (NFV) in treated patients with a sustained virological response. Concentrations of nucleoside analogs (NA) were measured in plasma as a secondary objective. A one-compartment model with first-order elimination was used, with zero-order absorption for LMV and first-order absorption for STV and ZDV. Results Mean parameters [interpatient variability in coefficient of variation (CV%)] of LMV, STVand ZDV were: oral volume of distribution (V/F) 145 l (52%), 24 l (81%) and 248 l (80%), oral clearance (Cl/F) 32 l/h, 16 l/h (74%) and 124 l/h (51%), respectively. For LMV, absorption duration (T a ) was 1.46 h (64%). For STV and ZDV, k a was 0.46 h −1 and 2.9 h −1 , respectively. We found a systematic effect of combination with NFV vs. IDV. We found that intrapatient variability was greater than interpatient variability (except for STV) and greater than 55% for the three drugs. Conclusion This trial enabled the estimation of the population PK parameters of three NA in patients with a sustained virological response, and the median curves could be used as references for concentration-controlled strategies. We observed, as for the protease inhibitors, a great variability of PK parameters.
Introduction
Therapeutic drug monitoring (TDM) of protease inhibitors (PIs) and nonnucleoside reverse transcriptase inhibitors has been largely investigated, and its importance has been demonstrated in special populations (pregnant women, hepatic failure, etc.). Pharmacokinetic (PK) studies performed in patients having an optimal response to highly active antiretroviral therapy (HAART) are the gold standard to define reference curves for TDM. For nucleoside analogs (NA), TDM is generally not recommended because the concentration/effect relationship has not been clearly defined and because NA in plasma need to be phosphorylated before becoming active in the cell. On the other hand, the potential interest of concentration-controlled regimens of NA has already been shown [1] [2] [3] [4] . However, very few data are available on the PK of NA in patients successfully treated with HAART. Such data are important to correlate plasma and intracellular concentrations and to establish a range of effective and nontoxic plasma concentrations of all components of HAART.
The COPHAR1-ANRS102 trial was a prospective, openlabel, multicenter trial, the primary objective of which was to study the PK of indinavir (IDV) and nelfinavir (NFV) in patients on sustained virological success. Reference therapeutic windows for the TDM of IDV and NFV were defined according to the concentration data measured in this trial [5] . The population approach was also used to describe the PK of IDV and NFV, to estimate inter-and intrapatient variabilities of the PK parameters, and to test the effect of covariates. An increase of IDV and NFV clearance was found in patients receiving zidovudine (ZDV) as part of their treatment [6, 7] . In COPHAR1-ANRS102, patients received either lamivudine (LMV), stavudine (STV), or ZDV as part of their treatment in addition to one protease inhibitor. As a secondary objective, NA concentrations were measured in the same plasma samples collected to study the PK of NFV and IDV. The aim of our study was to build a population PK model for LMV, STV and ZDV to estimate their inter-and intraindividual PK variability and to investigate the influence of different covariates on the PK parameters of these three drugs.
Materials and methods

Study design and patients
The COPHAR1-ANRS102 trial was a prospective, multicentre, open-label trial that included HIV-infected adults currently treated with an antiretroviral (ARV) combination of at least two drugs containing either IDV or NFV. Enrolment started in February 2001, and the last subject completed the study in October 2002. To be eligible, patients had to be treated with a stable regimen for at least 4 months, with a sustained virological response defined by a plasma HIV RNA level below 200 copies/ml for at least 4 months. The main exclusion criteria were the following: concomitant use of drugs interacting with IDV or NFV, renal failure (defined by a serum creatinine greater than 180 μmol/l), liver dysfunction (defined by a serum aminotransferase level greater than twice the upper limit of normal, a prothrombin test below 50% or a diagnosed liver cirrhosis), pregnancy, ongoing acute opportunistic infection or cancer.
All patients received the standard dose of 300 mg/day for LMV. The STV dose was prescribed according to subject's weight: 60 mg/day for subjects whose weight was less than 60 kg, and 80 mg/day for those whose weight was greater than 60 kg. The recommended standard daily dose for ZDV was 600 mg.
The Ethical Review Committee of the Bicêtre Hospital, Paris, France, reviewed and approved the study protocol. All participants provided written informed consent. At the screening visit (V0), inclusion criteria were checked. At visit 1 (V1), 1 month after inclusion, patients underwent a 6-h blood sampling for concentration assay. At visit 2 (V2), 4 months after inclusion, two additional blood samples were collected. The trial ended 8 months after inclusion (V3), when clinical, immunological and virological data were collected. Only patients with a sustained virological response, i.e. 4 months before inclusion plus 8 months after inclusion, were analysed.
Adherence was evaluated using a validated autoquestionnaire and applying the algorithm proposed by Carrieri et al. [8] . Patients were classified as highly adherent if they reported taking 100% of their prescribed regimen in the last 4 days, moderately adherent if they reported missing no more than 20% of their treatment, and nonadherent if they reported taking less than 80% of their treatment.
PK samples and concentration measurement PK sampling was designed according to the dosing regimen of the PIs. The interval between the last dose on the previous day and the morning dose was planned for 12 h (±2 h) for bid dosing and for 8 h (± 2 h) for tid dosing. At V1, plasma samples were collected before dosing (trough sample) and at 0.5, 1, 3 and 6 h after drug intake. At V2, a sample was collected 8 h (±2 h) or 12 h (±2 h) for tid and bid dosing, respectively, after the last drug intake, and a second sample 1 h after observed drug intake in patients treated with IDV alone, or 3 h after observed drug intake in patients receiving NFV or IDV/ritonavir in order to reach the C max of the corresponding PI. For each sample performed after the observed drug intake, the exact interval between last drug intake and blood sampling was recorded. For trough samples, the delay since last dose was evaluated from the time of last evening dose reported by the patient and the exact sampling time in the morning. All NA concentrations measured at V1 and NA concentrations measured 1 h (C 1h ) and 3 h after dose (C 3h ) measured at V2 are analysed were analysed. NA concentrations were measured in each plasma sample in a central laboratory of pharmacology in Paris. NA were isolated from alkaline plasma samples by double-step solid-liquid extraction, and their concentrations were determined by specific high-performance liquid chromatography assays with ultraviolet-photodiode array [9] . Interlaboratory quality control results at three concentrations (50, 400 and 1000 ng/ml for LMV and 25, 200 and 400 ng/ml for both STV and ZDV) were within 20% of the target values for the three NA. Lower limits of quantification (LOQ) were 20 ng/ml, 10 ng/ml and 10 ng/ml for LMV, STV and ZDV, respectively.
Population pharmacokinetic model
For each of the 3 NA, we tested a one-compartment model with first-order absorption or zero-order absorption to analyse concentrations measured at V1. The parameters of these two models are the first-order absorption rate constant (k a ) or the zero-order absorption duration (T a ), the apparent elimination clearance (Cl/F) and the apparent volume of distribution (V/F). With respect to timing assumptions, exact sampling times were taken for samples scheduled at 0.5, 1, 3 and 6 h after the morning dose. For modelling, we assumed that trough samples were obtained after the other measurements on the same PK profile. For each NA, the statistical model for the observed concentration C ij of patient i at the sampling time t ij is:
where θ i is the vector of the logarithm of all the PK parameters of patient i and ɛ ij is the measurement error. For each NA, we assumed that the errors ɛ ij given θ i are independent and normally distributed with a null mean and an heteroscedastic variance s 2 ij , which was modelled using a combined proportional and additive error model:
This combined error model (additive and proportional) is commonly used in population pharmacokinetics. For high concentrations, variance becomes proportional to the squared concentration, whereas for low concentrations, the variance becomes proportional to a 2 . When LMV, STV or ZDV concentrations were below the LOQ, we set them at LOQ/2 [10] . If several consecutive concentrations were below the LOQ, the first was set to the corresponding value of LOQ/2 and the others were removed from the analysis.
We assumed that the logarithm of the individual parameters θ i are random vectors and that θ i can be decomposed as:
where θ is the population mean vector of size p, and b i is the random effect of subject i, which is assumed to be normally distributed with zero mean and diagonal variance Ω. The standard deviations of the additive random effects on the log-transformed PK parameters are then a first-order approximation of the coefficient of variation (CV) of the original PK parameters. These standard deviations are the square roots of the diagonal elements of Ω.
The parameters were estimated using Lindström and Bates' algorithm implemented in the nlme function of R 2.0 software (R Foundation for Statistical Computing, Vienna, Austria) [11] [12] [13] . The estimates for the standard errors (SE) of the parameters were used to derive the corresponding asymptotic 95% confidence intervals (CI).
Modelling strategy
For each drug, we first selected the pharmacokinetic model (one compartment model with zero-order or firstorder absorption and first-order elimination) based on the Akaike criterion (AIC) [14] using a combined error model. We then selected the error model, starting with the previous combined error model where a and σ are estimated. We also tried a model where a is fixed, a model where a is fixed to zero and an additive error model. Using the best error model, selected according to the AIC, we built a model with random effects on all PK parameters. We used a backward elimination procedure to test whether each random effect should stay in the model. Goodness-of-fit plots (weighted residuals vs. predicted concentrations and vs. time) were examined for each model. Models were also compared using the AIC. For each NA and for each PK parameter whose random effect remained in the model, we evaluated the effects of the following covariates: age, gender, body weight, coadministered PI (NFV or IDV), coadministration of other ARV drugs (as a binary variable for each drug) and treatment adherence (as a categorical variable). We tested the covariates on the empirical Bayes estimates of each individual parameter using Spearman nonparametric correlation tests for continuous covariates and Wilcoxon or Kruskal-Wallis tests for categorical covariates with two or more than two categories, respectively. The population covariate model was then built with the covariates, which were found to have an effect on the empirical Bayes estimates with a p value smaller than 0.20. Continuous covariates were centred on their median. All population models with all combinations of these selected covariates were then evaluated. The combination with the smallest AIC was chosen as the best population covariate model. The p values of the covariates were then derived using the likelihood ratio test (LRT).
Model evaluation
We produced the goodness-of-fit plots (population-predicted concentrations vs. observed concentrations, individual-predicted concentrations vs. observed concentrations and population-weighted residuals vs. observed concentrations) for each of the three NA. We also simulated steady-state concentration profiles for the three NA studied and compared them with the observed data in order to evaluate the predictive performance of the model. More precisely, a vector of PK parameters was simulated for 5,000 patients using the final model of each NA. Each parameter vector was drawn in a normal distribution with a variance equal to the inter-patient variability estimated before. We simulated the covariates included in the final model, using the estimated distribution in the sample of patients. A simulated measurement error was added to each simulated concentration. We simulated 5,000 concentration profiles by increments of 0.01 h. The 10th, 50th and 90th percentiles of the simulated concentrations at each time were compared with the observed concentration data for the patients with the corresponding regimen. The 50th percentile of the simulated concentrations was compared with the observed median of concentration data estimated at 0.5, 1, 3 and 6 h after drug intake and for the trough concentration. For trough concentrations, we calculated the median from concentrations measured between 10 h and 14 h after drug intake, as there was an important variability of sampling time for that measurement. The simulations were performed using R 2.0 (R Foundation for Statistical Computing, Vienna, Austria) [13] .
Estimation of intrapatient variability
From the two concentration measurements of the same time at visit 1 and visit 2, we estimated the inter-and intrapatient variability for C 1h in patients receiving IDV alone and for C 3h in patients receiving IDV/ritonavir or NFV. We did not estimate the intrapatient variability of trough concentrations, as the time of drug intake on the previous day suffered from too much uncertainty. Moreover, since the sampling protocol had been designed for the two PIs, an important proportion of the NA trough concentrations were below the LOQ : 7.3% for LMV; 35.7% for STV and 46.3% for ZDV; therefore, the estimation of intrapatient variability would have been difficult. We used a linear mixed effects model and assumed that the logarithm of the individual concentrations y ik of patient i on visit k (k=1, 2) can be decomposed as:
where T i is equal to 0 if C 1h was analysed for subject i and 1 if C 3h was analysed; β is the effect quantifying the difference between concentrations measured 1 h and 3 h after drug intake, η i is the random effect of subject i with null mean and variance γ 2 and κ ik is the intraindividual random effect, with null mean and variance ψ 2 . Using a first-order approximation, γ and ψ are estimates of the inter-and intrapatient CV of the untransformed concentrations. The estimation was performed using the lme function of R 2.0 [12, 13] .
Results
Patients
Ninety-five patients were included in the COPHAR1-ANRS102 trial. Eighty-eight of them had a sustained virological response for the 8 months of follow-up and were analysed. The characteristics of these patients are shown in Table 1 . The pharmacokinetics of 54, 39 and 27 patients also receiving LMV, STV and ZDV, respectively, Tables 1 and 2 . For LMV, the only regimen was 150 mg twice daily. For STV, 31 patients received 40 mg bid and eight received 30 mg twice daily. For ZDV, 24 patients received 300 mg twice daily and three received 250 mg twice daily. The repartition of these patients between the two PI groups is shown in Table 2 .
Lamivudine
Two hundred and sixty-seven concentration data were obtained from the 54 patients receiving LMV (Fig. 1a) . Eight concentrations were below the LOQ; six were set to LOQ/2, and the other two were excluded, as they were consecutive to a first concentration found below the quantification limit. The one-compartment model with zero-order absorption and first-order elimination achieved the smallest AIC. Moreover, the model had to be parameterised in log(k) rather than log(Cl/F) to achieve convergence. A combined error model, where a was estimated, was selected. Random effects could be estimated on log(T a ) and log(V/F). The parameter estimates of this basic model are displayed in Table 3 . From the univariate selection performed on the individual parameters, several significant covariates were found on log(T a ) only: the coadministered PI, combination with ZDV, combination with STV, age, body mass index (BMI) and creatinine clearance. As a model with these six covariates did not achieve convergence, we performed a preselection using a multiple linear model with a backward selection on the individual parameters of log(T a ). The final model included the coadministered PI, age and BMI, and was therefore: The effect found for age corresponds to an increase of 36% of T a for an increase of 10 years of age (p=0.0143). The effect found for BMI corresponds to a decrease of 10% of T a for an increase of one BMI unit (p<10 −4 ). Parameter estimates are presented in Table 3 . Interpatient variability Time (h) ZDV concentration (ng/mL) Fig. 1 Observed concentrations of lamivudine (LMV) (a), stavudine (STV) (b) and zidovudine (ZDV) (c) and curve predicted for the fixed effects for patients comedicated with indinavir (IDV) (dashed line) and nelfinavir (NFV) (solid line). Two concentrations greater than 2,000 ng/ml are not displayed for STV was found to be large: 63.7% for log(T a ) and 52.1% for log (V/F). The predicted curve for the mean PK parameters corresponding to each coadministered PI are overlaid on the observed concentration data of LMV in Fig. 1a .
Stavudine
One hundred and eighty-two concentration data were obtained from the 39 patients receiving STV. Seventeen concentrations were below the LOQ and were fixed to LOQ/ 2. The one-compartment model with first-order absorption and first-order elimination achieved the smallest AIC. A combined error model with a fixed to 120 ng/ml was selected, and random effects could be estimated on log(Cl/F) and log(V/F). The parameter estimates of the basic model are displayed in Table 4 . The univariate covariate selection identified the coadministered PI, creatinine clearance and body weight as possibly significant factors explaining the variability observed on log(Cl/F). No covariate was found to be associated with log(V/F). The final model found for Cl/F included only NFV as a covariate and was:
where NFV equals 1 if patient received NFV as a part of treatment, and 0 otherwise. The oral clearance was found to be 56% higher in patients receiving NFV vs. IDV as a PI (p= 0.031). Inter-patient variability was found to be even larger than for LMV: 77.2% for log(Cl/F) and 82.4% for log(V/F). The predicted curve for the mean PK parameters corresponding to each coadministered PI are overlaid on the observed concentration data of STV in Fig. 1b .
Zidovudine
One hundred and thirty-three concentration data were obtained from the 27 patients receiving ZDV. Sixteen concentrations were below the LOQ; 14 were set to LOQ/2, and the other four were excluded, as they were consecutive to a first concentration found below the LOQ. The onecompartment model with zero-order absorption and first-order elimination achieved the smallest AIC. A combined error model with a fixed to 120 ng/ml was selected. Random effects could be estimated on log(Cl/F) and log(V/F). The parameter estimates of the model are displayed in Table 5 . The coadministered PI was the only possibly significant covariate found on both log(Cl/F) and log(V/F) during the univariate analysis performed on the individual parameters. The model used for Cl/F and V/F was therefore:
where NFV equals 1 if patient received NFV as a part of treatment, and 0 otherwise. The oral clearance and the oral volume were found to be 124% (p=0.0003) and 88% (p= 0.0263) higher in patients receiving NFV vs. IDV as a PI, respectively. Interpatient variability was found to be 50.9% for log(Cl/F) and 80.1% for log(V/F). The predicted curve for the mean PK parameters corresponding to each coadministered PI are overlaid on the observed concentration data of ZDV in Fig. 1c .
Model evaluation
The goodness-of-fit plots are displayed in Fig. 2 . They were satisfactory for the three studied NA. The adequation of the observed concentrations with the simulated 10th and 90th percentiles and the adequation of the 50th percentile with the median of the observed concentrations are displayed in the log scale in Fig. 3 . The model seems to underpredict residual concentrations for STV and ZDV. The percentage of concentrations outside the interval defined by 10th and 90th percentiles were 22.85%, 24.10% and 21.80% for LMV, STV and ZDV, respectively. We considered that these results were close enough to the expected value of 20% to keep the final model for the three NA.
Inter-and intrapatient variability
The observed C 1h and C 3h at the two visits are displayed in Fig. 4 . For each NA, the estimates of the inter-and intrapatient CV of these concentrations are shown in Table 6 , together with the CV for total variability. Both inter-and intrapatient variabilities were important. Moreover, intrapatient variability was greater than interpatient variability, except for STV, and was greater than 55% for the three NA. These large variabilities were not expected in patients with sustained virological response, as the exact sampling times and the exact time of drug intake, which took place at the hospital, were known for C 1h and C 3h .
Discussion
The COPHAR1-ANRS102 study, first designed to study the pharmacokinetics of PIs, allowed us to estimate the population PK parameters of three NA-LMV, STV and ZDV-together with their interpatient variability. Concentration data obtained at a second visit allowed us to estimate the intrapatient variability of concentrations. Population PK approach for NA has essentially been applied to analyse data obtained in patients treated with mono-or bitherapies [15] [16] [17] [18] [19] [20] [21] . A first-population analysis of all the components of an ARV treatment was performed in patients receiving a triple combination of nevirapine plus ZDV plus didanosine [22] and found a large intrapatient variability (greater than 50%) for ZDV. A population analysis of tenofovir in patients on HAART was also recently performed [23] Time (h) ZDV concentration (ng/mL) Fig. 3 Evaluation of the final model: comparison between the 10th, 50th (solid line) and 90th percentiles for the 1,000 simulations for patients receiving lamivudine (LMV) (a), stavudine (STV) (b) and zidovudine (ZDV) (c) with the observed data and the median of the observed concentrations measured at 0.5, 1, 3 and 6 h, and between 10 and 14 h for the trough sample (dark grey rectangles and dark grey line, respectively). Two concentrations greater than 2,000 ng/ml are not displayed for STV papers proposed reference concentration curves for the studied NA.
We observed a systematic interaction effect of combination with NFV vs. IDV for the three drugs. It resulted in lower ZDV concentrations in patients receiving NFV, which may be related to the induction of glucuronidation by NFV via an increase in activity of glucuronosyltransferase. It also resulted in lower STV concentrations in the NFV group, which may be due to the interaction of NFV on the hepatic enzymes involved in the metabolism of the drug. These results should be taken into account for the choice of ZDV or STV regimens when prescribed in combination with NFV. A decreased exposition to NFV in patients comedicated with ZDV was also found in COPHAR1-ANRS102 [7] , indicating that precautions should be taken when coprescribing these two drugs.
For LMV, the increased absorption duration in patients receiving NFV may be partly explained by a food effect. Indeed, patients of the NFV group received a light meal before drug intake. In the IDV group, the seven patients also receiving ritonavir were fed, whereas the other 17 receiving IDV alone took their medication in fasted conditions. Absorption of LMV has been shown to be slower in fed compared with fasted patients [24, 25] , which is in agreement with the increased T a observed in the NFV group. However, the clinical relevance of this effect and those of BMI and age seem small, as these covariates influence absorption duration, which has a smaller influence on the area under the curve (AUC). It should be noted that adherence measured at V1 by the auto-questionnaire was not found to significantly influence the PK parameters of the three NA.
We performed the population analysis from concentration data of the first visit only, as the model including data from both V1 and V2 could not be fitted using nlme for LMV and STV. We therefore estimated both inter-and intrapatient variability from the observed C 1h or C 3h measured at two occasions for the three NA. Both variabilities were important for the three drugs, and intrapatient variability was always greater than 55%, resulting in an overall variability of 85-155%, even greater than the variability found by Zhou et al. for ZDV [22] . As drug accumulation is very small for the three studied NA, as illustrated by the important proportion of trough concentra- tions below the LOQ, and as the exact time of drug intake is know for these measurements, this high intrapatient variability may be essentially due to an important variability of bioavailability, both absorption and presystemic metabolism. The simulated concentrations used for the graphs of Fig. 3 could be used to build reference intervals for NA concentrations. For the three NA, the logarithm of the 5,000 concentrations simulated 1 h after drug intake was distributed according to a normal distribution, with a variability of 82%, 67% and 61% for LMV, STV and ZDV, respectively. The corresponding within-patient variabilities were 67.7%, 56.8% and 122.9% (cf Table 4 ). A reasonable hypothesis is to perform TDM only for drugs with a within-patient variability of concentrations inferior to the interpatient variability used to define target concentration intervals. The within-patient variability observed for ZDV would therefore question the interest of TDM for this specific drug. However, results obtained for a single sampling time are not sufficient, and it would be necessary to analyse more complete PK profiles taken at several occasions to be able to better estimate withinpatient variability for these three drugs and connect it to safe and effective concentration intervals. The concentration-effect relationships, that are a prerequisite for TDM [26] , have only been demonstrated for some NA, and only when given in monotherapies [27, 28] . We could not study these relationships in this trial, as all patients had a sustained, undetectable viral load. We believe that if all the elements justifying TDM of NA are not available yet, concentration-controlled therapy of the NA composing HAART could be performed. Indeed, Kakuda et al. have already demonstrated the usefulness of this approach for a treatment composed of ZDV, LMV and IDV [4] . As patients of COPHAR1-ANRS102 achieved sustained virological response, the 50th percentile curves simulated to evaluate the final model for the three drugs (Fig. 2) could be used as reference curves for LMV, STV and ZDV. In Western countries, new combinations of NA have appeared since this trial, but the combination of LMV + ZDV remains largely prescribed, as well as new q.d. regimens, including LMV with either abacavir or tenofovir. LMV, STV and ZDV are still commonly used all over the world. It is therefore important to have an adequate reference PK profile obtained in patients with sustained virological response for the TDM of these three NA.
